Edition:
India

aTyr Pharma Posts Q2 Loss Per Share Of $0.69


Friday, 14 Aug 2020 

Aug 13 (Reuters) - aTyr Pharma Inc ::ATYR PHARMA ANNOUNCES SECOND QUARTER 2020 RESULTS AND PROVIDES CORPORATE UPDATE ON ATYR1923 CLINICAL TRIAL PROGRAMS.ATYR PHARMA - INITIATED ENROLLMENT OF PHASE 2 RANDOMIZED, DOUBLE BLIND, PLACEBO-CONTROLLED STUDY OF ATYR1923 IN COVID-19 PATIENTS.QTRLY LOSS PER SHARE $0.69.Q2 EARNINGS PER SHARE VIEW $-0.73 -- REFINITIV IBES DATA.